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Structural mechanism of synergistic activation of
Aurora kinase B/C by phosphorylated INCENP
Kamal R. Abdul Azeez1, Sneha Chatterjee2, Channing Yu 3,4, Todd R. Golub 3,4, Frank Sobott2,5,6 &
Jonathan M. Elkins 1,7
Aurora kinases B and C (AURKB/AURKC) are activated by binding to the C-terminal domain
of INCENP. Full activation requires phosphorylation of two serine residues of INCENP that are
conserved through evolution, although the mechanism of this activation has not been
explained. Here we present crystal structures of the fully active complex of AURKC bound to
INCENP, consisting of phosphorylated, activated, AURKC and INCENP phosphorylated on its
TSS motif, revealing the structural and biochemical mechanism of synergistic activation of
AURKC:INCENP. The structures show that TSS motif phosphorylation stabilises the kinase
activation loop of AURKC. The TSS motif phosphorylations alter the substrate-binding sur-
face consistent with a mechanism of altered kinase substrate selectivity and stabilisation of
the protein complex against unfolding. We also analyse the binding of the most speciﬁc
available AURKB inhibitor, BRD-7880, and demonstrate that the well-known Aurora kinase
inhibitor VX-680 disrupts binding of the phosphorylated INCENP TSS motif.
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There are three Aurora kinases in mammals, Aurorakinase A, Aurora kinase B and Aurora kinase C(AURKA, AURKB and AURKC). Although the kinase
domains of the Aurora kinases have signiﬁcant homology
(AURKC has 84% and 68% sequence identity to AURKB and
AURKA, respectively) and their ATP binding sites are 100%
conserved, they have different regulatory mechanisms and
perform different functions. AURKA and AURKB catalyse
critical phosphorylation events in mitosis while AURKC is
mainly expressed in gametes and is important for meiosis:
micro-injection of inactive AURKC into mouse oocytes (in
which AURKB protein was not detected) caused cytokinesis
failure in meiosis I, with errors in chromosome alignment and
segregation1. In a similar manner, an AURKC ATP binding site
mutant injected into mouse oocytes also caused arrest at
meiosis I for the majority of oocytes, although some did pro-
ceed through cytokinesis normally2. This suggested that, as well
as the regulation of the spindle assembly checkpoint in meiosis
by an AURKC chromosomal passenger complex (CPC), there is
also the possibility for an AURKB CPC to perform this func-
tion2. However, the oocytes that did proceed despite lack of
AURKC activity were aneuploid, showing the importance of
AURKC for chromosome segregation in meiosis. It has been
suggested that AURKC compensates for lack of AURKB during
maturation of the early embryo and that it achieves this
through greater protein stability during the single cell stage
(meiosis) and in early cell divisions3. Indeed, AURKB but not
AURKC was shown to be dispensable during early cell divi-
sions4. AURKC lacks some protein degradation markers found
in AURKB and so one current model is that AURKC provides a
longer lasting version of AURKB that will be present through
meiosis. In artiﬁcial systems AURKC is able to substitute for
AURKB in mitosis5,6, suggesting again that it is the regulation
of AURKB and AURKC protein levels which is important
rather than intrinsic differences between the kinase domains.
AURKB is found in the CPC together with the inner cen-
tromere protein (INCENP), borealin and survivin7–9. Forma-
tion of the CPC and correct localisation of the CPC is essential
for a properly ordered sequence of events in the exit from
mitosis. AURKC is also found in the CPC and is also activated
by INCENP10. AURKB and AURKC are bound to the C-
terminal “IN-box” region of INCENP11. This IN-box region
contains a conserved C-terminal TSS motif; in C. elegans this
motif (GSS in C. elegans) is a substrate of AURKB (AIR-2) and
TSS motif phosphorylation increases AURKB activity12. Similar
results were obtained with human AURKB and INCENP13.
These two phosphorylation sites are conserved through
evolution11,12 pointing to an essential and fundamental role of
the TSS motif. Previous crystal structures of human or X. laevis
AURKB bound to INCENP revealed an extensive interaction of
AURKB with the C-terminal IN-box region14,15. However,
these previous structures were of partially active AURKB:
INCENP complexes lacking a phosphorylated TSS motif and
thus the mechanistic role of this evolutionarily conserved motif
has not been explained.
To understand better the molecular mechanisms of regulation
of AURKB and AURKC by INCENP we determined structures of
fully active (phosphorylated) human AURKC bound to the
phosphorylated C-terminal IN-box section of human INCENP
(residues 835–903). These structures demonstrate the structural
changes upon activation and the roles of essential conserved
residues. We show that the TSS motif phosphorylations activate
AURKB and AURKC by changing the KM for substrate. In
addition, we present crystallographic and biophysical character-
isation of a potent and extremely selective AURKB and AURKC
inhibitor16.
Results
Structure determination of activated human AURKC:INCENP.
To initiate structural and biochemical studies on AURKB and
AURKC INCENP complexes we constructed plasmids for bi-
cistronic co-expression of the INCENP IN-box (residues
835–903) with AURKB or AURKC kinase domains. Various
truncations of AURKB and AURKC were assessed for production
of soluble and stable Aurora:INCENP complexes with several of
each producing high yields of soluble protein (Supplementary
Table 1). In all puriﬁed protein complexes, electrospray ionisation
mass spectrometry revealed two stoichiometric phosphorylations
of INCENP, a sub-stoichiometric third INCENP phosphoryla-
tion, and 1–3 phosphorylations of AURKB or AURKC (Supple-
mentary Fig. 1). Several of the phosphorylated AURKC:INCENP
protein complexes were used in crystallisation trials together with
the ATP-competitive dual AURKB/AURKC-speciﬁc inhibitor
BRD-788016. A complex containing residues 36–305 of AURKC
isoform 1 gave crystals which diffracted to 1.75 Å resolution
(Table 1). It was possible to solve the structure from this data by
the molecular replacement method using a model of human
AURKB15 and then to build and reﬁne a model of AURKC:
INCENP. The ﬁnal model contains residues 36–303 of AURKC
and residues 838–903 of INCENP (Fig. 1a). The electron density
clearly showed that AURKC residues Thr39 and Thr198 were
phosphorylated, as were INCENP residues Ser893 and Ser894
(Supplementary Fig. 2). The third INCENP phosphorylation site
was not identiﬁed and since all INCENP serine or threonine
residues were clearly resolved in the electron density it may be
that crystallisation selected only the AURKC:INCENP complexes
without the third INCENP phosphorylation.
The phosphorylated TSS motif binds the AURKC activation
loop. AURKC Thr198 is the canonical activation loop residue
that in many Ser/Thr kinases is phosphorylated as part of the
activation mechanism of the kinase. Phosphorylation of kinases at
this conserved site causes the activation loop to adopt a more
ordered arrangement that forms part of the substrate binding
surface. The phosphorylated Thr198 (pThr198) is bound as
expected by the side-chain of Arg165 from the kinase’s HRD
motif (Fig. 1b), a feature common to the activation mechanism of
protein kinases. pThr198 is also bound by the side-chains of
Arg90 from the αC helix, a feature in common with activated
AURKA:TPX217, and Arg196 from the activation loop.
Unexpectedly, Arg196 also forms hydrogen bonds with both of
the phosphorylated INCENP residues pS893 and pS894 (Fig. 1b,
c). INCENP pS893 forms hydrogen bonds with AURKC Arg196,
Thr191 and Ser193 which are all located on the activation loop.
INCENP pS894 forms hydrogen bonds with AURKB Arg196 and
Arg90, as well as with INCENP Arg887 and Arg191. All of the
AURKC activation loop residues (184–209) except Thr191 are
conserved in AURKB (Fig. 1d and Supplementary Figs. 3 and 4)
and so it is very likely that AURKB has a similar activation loop
conformation in its active form. Of particular interest, with the
exception of Thr191, all AURKC residues involved in binding
INCENP pS893 and pS894 are highly conserved through
evolution (Fig. 1d), even in organisms such as Saccharomyces
cerevisiae and Arabidopsis thaliana where the putative INCENP
protein lacks the TSS motif (Supplementary Fig. 5). Furthermore,
other adjacent INCENP residues are also highly conserved, and
these have conserved binding positions on AURKC. In particular,
INCENP Trp897 is bound in an aromatic stacking interaction by
AURKC His97 and His190; these AURKC residues are conserved
except where the INCENP equivalent does not have a
corresponding tryptophan. Arg891 forms salt bridges with both
pS894 and Glu93 from αC of AURKC (Fig. 1) which appears to
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11085-0
2 NATURE COMMUNICATIONS |         (2019) 10:3166 | https://doi.org/10.1038/s41467-019-11085-0 | www.nature.com/naturecommunications
be an essential interaction in the binding of the TSS motif. Just
two of the residues that appear to be important for INCENP TSS
motif binding are not highly conserved: Arg887 which binds
pS894 (Fig. 1) is conserved only in the higher mammals, which
have an AURKC enzyme. The same is also true for the adjacent
Tyr888 which binds against AURKC αC and forms a hydrogen
bond with Glu85.
The AURKC conformation around pThr198 is broadly similar
to that seen in active AURKA17 (Supplementary Fig. 6), although
with a different conformation of Arg196 to allow Arg196 to form
hydrogen bonds simultaneously to pThr198 and INCENP
pSer893 and pSer894 (Fig. 1b), and crucially with a ﬂip of the
backbone conformation at residues 193–195 which directs
Leu194 away from INCENP (Fig. 1b). In previous structures of
Xenopus laevis AURKB:INCENP14, which have a phosphorylated
activation loop but lack the C-terminal region of INCENP, the
AURKB residue equivalent to AURKC Leu194 is directed towards
INCENP, and is in a position incompatible with binding of
INCENP pS893 (Supplementary Fig. 6). Thus, the data is
consistent with a mechanism where binding of INCENP pS893
and pS894 promotes a ﬂip of the activation loop at Leu194, a
change in conformation of Arg196, and hydrogen-bonding of
pThr198 with Arg90. The conformation of the activation loop in
the Xenopus laevis AURKB structures can therefore be considered
as partially activated. In our previous structure of partially active
Homo sapiens AURKB:INCENP15, which lacks phosphorylation
on the activation loop, the activation loop formed a domain-swap
dimer, made more favourable by hydrophobic interactions
involving AURKB Met249; such domain-swaps can be a
mechanism of trans-phosphorylation during activation18.
AURKB Met249 is not conserved in AURKC (Supplementary
Fig. 3), and so it seems less likely that there could be such a
domain-swap arrangement for inactive AURKC. Nevertheless it
remains possible that both AURKC and AURKB are activated by
trans-phosphorylation of their activation loops and either cis or
trans-phosphorylation of INCENP.
Compared with partially active AURKB:INCENP15 a much
longer piece of the INCENP IN-box is in an ordered conforma-
tion and bound to the kinase domain (Fig. 1e–g and
Supplementary Fig. 7). The conserved hydrophobic residues
Ile872, Leu875, Leu877, Ile880 and Phe881 were previously
identiﬁed as being important for INCENP binding to AURKB
αC15. All of these residues bind to the top face of αC, while
INCENP 887–901 binds against the bottom face. The aromatic
stacking interaction between INCENP Trp897 and AURKC
His97 and His190 is prominent and, combined with the extensive
hydrogen bonding network around INCENP pS893 and pS894,
ensures that both sides of αC and the activation loop are held in
an active conformation.
TSS motif phosphorylations contribute to kinase activation.
After seeing that the TSS motif phosphorylations were involved
both in stabilising the conformation of the activation loop and in
stabilising helix αC, we speculated that lack of TSS motif phos-
phorylation would alter the substrate afﬁnity/selectivity of the
Aurora:INCENP complex. To test this hypothesis we over-
expressed and puriﬁed AURKB:INCENP and AURKC:INCENP
complexes containing TSS motif mutations S893A or S894A
which prevent phosphorylation. We also tested W897A; Trp897
is adjacent to the TSS motif and forms substantial binding
interactions with AURKC, in particular an aromatic stacking
“sandwich” between His90 and His197 (Fig. 1e) and we reasoned
that W897A might also destabilise the active conformation of
INCENP bound to AURKB or AURKC. These complexes were
used in real-time enzymatic assays to measure KM for a generic
peptide substrate. All three mutations resulted in a reduced rate
of reaction with peptide substrate (Fig. 2a, b), as well as a reduced
rate of auto-phosphorylation when in the absence of a peptide
substrate (Supplementary Fig. 8). Analysis of the initial rates of
reaction by non-linear regression to a Michaelis–Menten model
allowed calculation of the KM(substrate) and Kcat values for the
reaction (Fig. 2c, d); while the Kcat values were largely similar
except for S894A (which is the most buried of the mutated
residues and has the most hydrogen bonds), the KM was in all
cases signiﬁcantly increased by the lack of TSS motif phosphor-
ylation. This leads to the conclusion that INCENP TSS motif
phosphorylation changes the substrate selectivity of the AURKB
Table 1 Data collection and reﬁnement statistics
AURKC: INCENP: BRD-7880 AURKC: INCENP: VX-680 AURKA: BRD-7880
PDB ID 6GR8 6GR9 6GRA
Space group P212121 P3121 P6122
No. of molecules in the asymmetric unit 1 1 1
Unit cell dimensions a, b, c (Å), α, β, γ (°) 56.7, 72.5, 83.1
90.0, 90.0, 90.0
82.6, 82.6, 121.0
90.0, 90.0, 120.0
83.2, 83.2, 171.9
90.0, 90.0, 120.0
Data collection
Resolution range (Å)a 56.65–1.75 (1.78–1.75) 71.55–2.25 (2.32–2.25) 85.93–2.60 (2.74–2.60)
Unique observationsa 34077 (1433) 23264 (2104) 11497 (1603)
Average multiplicitya 5.4 (4.1) 5.2 (4.9) 8.6 (8.3)
Completeness (%)a 97.1 (77.3) 100.0 (100.0) 100.0 (100.0)
Rmergea 0.10 (0.58) 0.07 (0.66) 0.07 (0.77)
Mean ((I)/σ(I))a 9.8 (2.1) 14.8 (2.0) 13.3 (2.4)
Mean CC(1/2) 0.995 (0.709) 0.999 (0.689) 0.999 (0.818)
Reﬁnement
Resolution range (Å) 54.61–1.75 71.55–2.25 66.52–2.60
R-value, Rfree 0.18, 0.22 0.18, 0.22 0.21, 0.27
r.m.s. deviation from ideal bond length (Å) 0.008 0.008 0.008
r.m.s. deviation from ideal bond angle (°) 1.35 1.33 1.29
Ramachandran outliersb most favoured 0.31%
97.5%
0.00%
96.03%
0.00%
97.15%
Average B-factors (protein, ligand, solvent) (Å2) 19, 16, 28 46, 40, 42 80, 73, 63
aValues within parentheses refer to the highest resolution shell
bValues from molprobity
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or AURKC complexes, as expected for a mechanism in which
phosphorylated INCENP stabilises the activation loop and these
two motifs together provide the binding site for the substrate.
TSS motif phosphorylation stabilises Aurora:INCENP. Struc-
ture comparison with partially active AURKB:INCENP reveals
the extent of the disorder-order transition on moving to the active
conformation (Supplementary Fig. 7). Since the active con-
formation has a phosphorylated kinase activation loop, as well as
the phosphorylated INCENP TSS motif we wanted to verify that
the INCENP TSS motif phosphorylations themselves make a
signiﬁcant contribution to this transition. We prepared com-
plexes of AURKC:INCENP, AURKC:INCENP-S894A and
AURKC:INCENP-S893A/S894A/W897A. S894A would be
expected to disrupt the majority of the hydrogen bonding around
the phosphorylated TSS motif while the triple-mutant complex
was prepared to give the maximum chance of distinguishing the
effect of the TSS motif. We hypothesised that the mutant com-
plexes would have greater structural ﬂexibility in the region of the
TSS motif, which would be less strongly bound to AURKC. The
mutant complexes would therefore have a different average shape
and cross-sectional area compared to wild-type (Fig. 3a, b).
We utilised native electrospray ionisation (ESI) with ion
mobility-mass spectrometry (IM-MS) to measure the degree of
complex formation (% bound, at a concentration of ca. 10 µM),
collision cross sections (rotationally averaged sizes, CCS) and
intrinsic stabilities (gas-phase collision-induced unfolding pro-
ﬁles) of these AURKC:INCENP complexes. First, native MS
showed that, under the experimental conditions used, with the
wild type INCENP virtually 100% AURKC:INCENP complex is
formed, while each of the INCENP mutant samples contained
signiﬁcant unbound AURKC (Fig. 3c) and unbound INCENP
despite the proteins being puriﬁed in the same way and the
analysis in the mass spectrometer being done with the same
energies. This is consistent with loss of the hydrogen bonds to the
INCENP phosphoserines leading to a weaker AURKC:INCENP
interaction for the mutants. Second, the INCENP mutants
showed slightly but signiﬁcantly reduced ion mobility drift times
(Fig. 3d, e) and, consequently, reduced collisional cross-sections
(Fig. 3g), implying that conformations of the ordered protein are
on average more compact. Third, the mutants showed an altered
gas-phase unfolding proﬁle with some unfolding transitions
occurring at lower collision energies in the triple mutant (Fig. 3f).
While the single INCENP S894A mutation displayed an effect,
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Fig. 1 Phosphorylated INCENP binds the activation loop of Aurora kinase B/C. a Structure of activated AURKC bound to the phosphorylated INCENP “IN-
box”. b, c Views from two angles showing how the phosphorylated INCENP makes extensive hydrogen-bonding interactions with the activation loop and
αC-helix of AURKC, and contributes signiﬁcantly to arranging the active conformation and substrate binding region of the kinase. d Sequence alignment of
the αC and activation loop regions of AURKB or AURKC from diverse organisms. Residues involved in binding INCENP are marked with triangles below the
alignment. For a full sequence alignment and sequence accession numbers see Supplementary Fig. 4. The sequence alignment was created using
ClustalO46 and Aline47. e In the fully active AURKC:INCENP structure INCENP makes contact with the Aurora kinase N-lobe and C-lobe, and the activation
loop. f, g Views from two angles showing how INCENP binds on two sides of AURKC αC including an aromatic stacking interaction between INCENPW897
and AURKC H97 and H190, as well as the hydrogen-bonding network around INCENP pS893 and pS894. These binding interactions link AURKC αC and
activation loop into a stable conformation, and the INCENP phosphorylations help to form the substrate binding groove, thus activating AURKC to different
substrates
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S893A/S894A/W897A showed a larger change (Fig. 3g) consistent
with a model in which binding of the phosphorylated TSS motif
serine residues and Trp897 provide additional stability to the
AURKC:INCENP complex.
To analyse the relative accessibility of the INCENP and AURKC
phosphorylations, the rate of dephosphorylation was assessed by
incubating AURKB:INCENP or AURKC:INCENP complexes
with the bacteriophage lambda phosphatase and monitoring by
ESI-MS. The data shows that INCENP dephosphorylation occurs
at least simultaneously and likely before dephosphorylation of the
kinase (Supplementary Fig. 9). Dephosphorylation of the com-
plexes with INCENP mutations appeared marginally faster in all
cases (two examples shown in Supplementary Fig. 10) but
experimental variables including differing phosphatase speciﬁcity
for the mutants cannot be ruled out.
VX-680 partially disrupts activation loop and TSS motif. To
provide additional support that the observed conformations of
INCENP and AURKC in the crystal structure were not due to
crystal packing considerations, we also co-crystallised the activated
AURKC:INCENP complex with the pan-Aurora kinase inhibitor
VX-680 (tozasertib) (Fig. 4a). Crystals of AURKC:INCENP bound
to VX-680 grew under different conditions to those with BRD-
7880 and were in a different crystal form (Table 1). The best
crystal diffracted to 2.25 Å resolution and allowed determination
of the structure by molecular replacement using the coordinates of
AURKC from the BRD-7880 co-crystal structure. In the ﬁnal
model INCENP binding and the activation loop conformation are
conserved (Supplementary Fig. 7), but binding of the region of
INCENP containing the TSS motif to AURKC is partly disrupted.
The TSS phosphorylations are clearly bound to AURKC in the
same conformation as seen in the BRD-7880 co-crystal structure
(Fig. 4b), conﬁrming the binding mechanism, however this
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Fig. 2 Enzymatic assays of AURKB or AURKC with wild-type or mutant INCENP. Mutation of the INCENP phosphorylation sites Ser893 or Ser894, or of
INCENP Trp897 which is also important for Aurora kinase:INCENP binding, altered the enzymatic properties considerably. All measurements were made in
triplicate. a Loss of TSS motif binding decreases the reaction rate for both AURKB and AURKC on a peptide substrate. b Quantiﬁcation of the rate of
reaction during the linear reaction phase of a. Error bars show standard error from the linear regression. c Measurement of initial rate of reaction (V0) at
varying peptide substrate concentrations, with curves calculated by non-linear regression (curve-ﬁtting) to the Michaelis–Menten equation. Calculated KM
and Kcat values from non-linear regression are shown in Table 2; the mutants show signiﬁcant variation in KM but similar Kcat values (with the possible
exception of S894A)
Table 2 KM and Kcat values from non-linear regression of the
data in Fig. 2c
INCENP Kcat (103 s−1) Km(peptide) (μM)
AURKB w.t. 50.8 ± 1.5 10.8 ± 1.5
S893A 50.1 ± 0.9 75.5 ± 3.6
S894A 32.9 ± 0.7 90.6 ± 4.7
W897A 51.9 ± 1.2 47.1 ± 3.2
AURKC w.t. 48.8 ± 2.3 18.7 ± 3.6
S893A 46.3 ± 1.4 83.0 ± 6.1
S894A 38.8 ± 0.6 83.0 ± 3.1
W897A 41.8 ± 0.9 25.1 ± 1.9
Note: The data shown are the best-ﬁt values ± standard error
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binding is weaker with disrupted hydrogen bonding from
pThr198 to Arg90, and Arg887 to pSer894, while the critical
INCENP residues for binding pS894, Arg887 and Arg891, are
disordered. The binding of INCENP Trp897 to the C-terminal end
of AURKC αC is maintained (Fig. 4c).
These observations suggested that either the new crystal form
or the presence of VX-680 disrupts the proper conformation of
the N-terminal part of αC and αB, preventing proper binding of
INCENP to form the activated conformation. Comparison of the
AURKC:INCENP structure with VX-680 to the structure with
BRD-7880 revealed a rotation of the N-lobe relative to the C-lobe
as also seen in the comparison of AURKA:TPX2:ADP and
AURKA:TPX2:VX-680 (Fig. 4d); this rotation results in a
movement of αC and especially αB, and is presumed to be
responsible for the partial disorder of INCENP relative to the
structure with BRD-7880. Overall, the AURKC:INCENP:VX-
680 structure superimposes with AURKB:INCENP:VX-680 better
than does the AURKC:INCENP:BRD-7880 structure, with a r.m.
s.d. of 0.67 Å over 172 Cα AURKC atoms compared to 0.80 Å
over 177 Cα atoms for the BRD-7880 structure which ﬁts with the
model of conformational change induced by VX-680.
Analysis of BRD-7880 binding and AURKA/AURKB selectiv-
ity. BRD-7880 was identiﬁed as a potent and speciﬁc AURKB
inhibitor with a similar activity proﬁle against cancer cell lines as
VX-680 and Ki values against AURKB and AURKA of 4 nM and
1570 nM, respectively16. The co-crystal structure with AURKC:
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Fig. 3 TSS motif binding affects AURKC:INCENP binding and shape. a, b Models of the effect of loss of TSS motif binding from a phosphorylated and
ordered INCENP TSS motif as seen in the crystal structure (a) to an unphosphorylated TSS motif and disordered C-terminal part of INCENP (b). c Native
mass spectra of AURKC:INCENP complexes show that under the same gentle ionisation conditions the wild-type AURKC:INCENP complex remains intact
while the non-phosphorylated INCENP mutants are only partially bound. This is shown by the single peak series around m/z 3000–3200 for the wild-type
AURKC:INCENP complex (MW expected 40501 Da, observed 40747 Da; one AURKC phosphorylation and two INCENP phosphorylations), while there are
separate charge state series for the individual AURKC and INCENP proteins when samples of INCENP mutant complexes were measured (AURKC:
INCENP-S894A MW expected 40059 Da, observed 40224Da; one AURKC phosphorylation and one INCENP phosphorylation, and AURKC:INCENP-
S893A/S894A/W897A MW expected 39928 Da, observed 40009 Da; one AURKC phosphorylation). d, e Without a phosphorylated INCENP TSS motif
the AURKC:INCENP complexes have shorter ion mobility drift times (12+ and 13+ charge states shown). f Collision-induced unfolding shows the AURKC:
INCENP mutant complexes reach the greatest extension already at lower energies consistent with greater structural ﬂexibility. g The experimental CCS
values of the AURKC:INCENP complexes were calculated after calibration from the ion mobility drift times. At all charge states the INCENP mutant
complexes have a reduced collision cross-section consistent with a reduced size of the compact, ordered and folded protein domain
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INCENP reveals a completely ordered BRD-7880 molecule
(Fig. 5a) which binds in the ATP-binding site. The benzo-1,3-
dioxole moiety (Fig. 5e) forms a hydrogen bond to Tyr122 on the
kinase hinge region, the central 8-membered ring forms a perfect
shape complementary binding over Leu173 and Ala183, the urea
motif binds over the DFG motif, while the terminal methox-
yphenyl moiety binds against the αC helix in particular Leu88 and
Glu91. The binding of the methoxyphenyl in front of Glu91
pushes Glu91 back towards Gln95 (Fig. 5a), closing the pocket
between Glu91 and Gln95 often seen in previous structures of
AURKB with inhibitors14,19,20 (and as seen with our AURKC:
INCENP:VX-680 structure).
Interestingly the urea motif is inserted between, and forms
hydrogen bonds to both of, Lys72 and Glu91, which would
normally form a salt bridge in an active conformation. Lys72 also
forms a hydrogen bond to the oxygen of the inhibitor’s cyclic
amide and to the backbone of the glycine-rich loop at Lys53.
Lys53 forms hydrogen bonds with Asp184 of the DFG motif,
which is linked via a hydrogen bond to the backbone nitrogen of
Gly186. Thus, there is a comprehensive set of hydrogen bonds
joining BRD-7880, the glycine-rich loop, the DFG motif and
Glu91 from the αC helix. The eight-membered ring at the core of
BRD-7880 allows it to have excellent shape-complementarity with
AURKC, while the hydrogen bonding between Lys53 and Asp184
partially encloses BRD-7880 within the binding pocket (Fig. 5b).
For further assessment of the selectivity of BRD-7880 for
AURKB/AURKC over AURKA, and in particular to examine the
effect on selectivity or potency caused by INCENP binding to
AURKB or TPX2 binding to AURKA, we conducted biophysical
interaction studies. Isothermal Titration Calorimetry (ITC)
provided KD values of 16 nM and 341 nM for BRD-7880 binding
to AURKB:INCENP or AURKA (no TPX2), respectively (Fig. 5c,
Supplementary Table 2). The greater afﬁnity of BRD-7880 for
AURKB is due to a more favourable entropy term, with the
enthalpy of binding being very similar to that for AURKA as
expected from the conservation of active site residues between
AURKB and AURKA.
We also attempted to measure the binding of BRD-7880 to
AURKA:TPX2 which would provide a truer comparison of the
selectivity of BRD-7880. However, injection of pre-prepared
AURKA:TPX2 complex into BRD-7880 solution was endother-
mic, with a very low N (stoichiometry) value (Fig. 5d).
Repetition of this experiment in a high (500 mM NaCl) salt
buffer produced still larger endothermic peaks, while a control
injection of AURKA:TPX2 into buffer produced very small
endothermic peaks (Supplementary Fig. 11). One possible
explanation is that BRD-7880 causes a loss of some of the
AURKA:TPX2 binding interactions; in this situation the ITC
experiment measures two binding events, one exothermic and
one endothermic, and we have not attempted to derive a KD
value for the AURKA:TPX2:BRD-7880 interaction except to
observe that the binding of BRD-7880 to AURKA is much
weaker in the presence of TPX2.
Binding of TPX2 to AURKA was previously shown to increase
afﬁnity for both ATP and a substrate peptide21, while the KM(ATP)
of AURKA is substantially decreased in the presence of TPX2 (1.7
µM vs. 27 µM)22. The EC50 for activation of AURKA by TPX2 was
measured as 2.3 nM21. However, TPX2 binding to AURKA
decreased afﬁnity of AURKA for two out of three inhibitors tested,
including VX-68021. The single inhibitor whose IC50 against
AURKA was not affected by TPX2 was one that is not predicted
to interact with helix αC21. Thus, TPX2 favours binding of ATP and
disfavours binding of inhibitors that disrupt an active conformation.
Given that BRD-7880 does interact with αC, and breaks the
important Lys-Glu interaction, the reduction in its binding afﬁnity
to AURKA in the presence of TPX2 is expected.
AURKA:BRD-7880 vs AURKA:VX-680 vs AURKA:TPX2:ADP
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Fig. 4 VX-680 binding partially disrupts AURKC:INCENP and affects the substrate binding groove. a Crystal structure of AURKC:INCENP:VX-680. AURKC is
in magenta for the N-lobe, blue for the C-lobe and orange for the activation loop. INCENP is shown in green, VX-680 in yellow. The parts of the AURKC:
INCENP:BRD-7880 structure that differ in position from the structure with VX-680 are shown in grey, illustrating the parts of AURKC:INCENP disrupted by
VX-680 binding. b VX-680 binding to AURKC disrupts INCENP binding to the activation loop, disrupting the substrate binding surface. INCENP is shown in
green and the part of INCENP not observed in the crystal structure is shown in grey, based on the structure of AURKC:INCENP:BRD-7880. c Binding of
INCENP Trp897 to the C-terminal part of AURKC αC is maintained in the presence of VX-680. d A crystal structure of AURKA with BRD-7880 shows that
the binding mode of BRD-7880 is conserved. Comparison of this structure with previously published structures of AURKA with VX-680 shows that, as with
AURKC, BRD-7880 allows an Aurora kinase conformation resembling the active form exempliﬁed by AURKA:TPX2:ADP, while VX-680 causes a rotation of
the N-lobe that disrupts the positions of αB and αC. A 2Fo–Fc electron density map is shown in blue around BRD-7880, contoured at 1.0 σ (0.14 eÅ−3)
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BioLayer Interferometry (BLI) measurements (Fig. 5f) revealed
that BRD-7880 bound to AURKA:TPX2 with fast kinetics and to
AURKB:INCENP with slow kinetics (ka ~ 0.017 s−1µM−1, it was
not possible to determine an accurate value for kd due to the slow
off-rate, but conservatively t1/2 >2000 s for dissociation). A crystal
structure of BRD-7880 bound to AURKA (in the absence of
TPX2) conﬁrms that the binding mode of BRD-7880 is identical
to that when bound to AURKC (Figs. 4d, 5g, Table 1), including
that the DFG motif of both AURKA and AURKC is in the DFG-
in position, although the two motifs do not superimpose
perfectly, likely due to the disordered activation loop in the
AURKA:BRD-7880 structure.
Taken together, these data show that the selectivity for AURKB
over AURKA seen in the enzymatic assays16 is due to favourable
entropy of binding and a longer residence time with AURKB.
The ITC and crystal structure data suggest that a major reason for
the good selectivity of BRD-7880 is that it can bind to AURKB or
AURKC without disturbing INCENP binding, but does not bind
to an intact AURKA:TPX2 complex.
Discussion
Previously it was shown that sub-stoichiometric INCENP is sufﬁcient
for AURKB activation by phosphorylation at Thr23223. This ﬁts with
a mechanism where INCENP pS893/pS894 alters the substrate
selectivity of AURKB/AURKC towards itself, enabling auto-
activation by phosphorylation in trans. The structure of partially
active AURKB:INCENP contains an activation loop domain swap;15
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this may be a mechanism for phosphorylation of non-consensus
sites18, and it is possible that phosphorylation of the INCENP TSS
motif by AURKB also proceeds in trans, while INCENP is bound to
an interacting kinase domain. Interestingly however, the AURKB
residues Met249 and His250 (isoform 1 numbering) which are
important in the formation of the AURKB dimerisation interface15
are not conserved in AURKC, and indeed in all of our experiments
AURKC:INCENP appeared monomeric.
Recent reports have presented data on the dynamic conforma-
tional equilibrium of the AURKA activation loop, and the change in
this conformational ensemble during activation by phosphorylation
and TPX2. The data suggest that the phosphorylated activation loop
shifts to a more ordered state in solution only upon TPX2 binding,
accompanied by a population shift towards a DFG-in state24–26, and
that phosphorylation itself alters the structure of the DFG-in state
rather than causing a population shift away from the DFG-out
state24, and that TPX2 binding can override the effects of inhibitors
on activation loop conformation27. The data so far on AURKB and
AURKC suggest the possibility of a similar mechanism. With a
phosphorylated activation loop, but without phosphorylated
INCENP binding, the activation loop does not form all hydrogen
bonds expected at its phosphothreonine and adopts a partially active
conformation, whereas in the presence of phosphorylated INCENP
the activation loop is fully engaged (Fig. 1b, Supplementary Fig. 6).
Previously it was shown that TPX2 binding protects AURKA from
activation loop dephosphorylation17,21,28,29, supporting a mechanism
in which the AURKA activation loop is less ﬂexible in the presence of
TPX2. Although analysis of AURKB and AURKC dephosphorylation
kinetics is complicated by the concomitant dephosphorylation of
INCENP, the data is at least consistent with reduced ﬂexibility of the
AURKC activation loop and the INCENP TSS motif, when the TSS
motif is phosphorylated.
While INCENP TSS motif phosphorylation occurs readily and to
completion during co-expression with AURKB/C in bacteria, in
human cells there are a variety of additional proteins effecting reg-
ulation of Aurora kinase activation. The data presented here shows
that the TSS motif is best described as a TSSxxW motif, while
additional conserved residues are involved in the activation
mechanism.
Recently it was reported that INCENP is mono-methylated on
Arg887 by PRMT1, and that this promotes mitosis of cancer cells30.
Knockdown of PRMT1 reduced phosphorylation of histone H3
Ser10 (H3S10), a key substrate of AURKB in the mitotic process,
and also the levels of phosphorylated AURKB Thr232, indicating
that activation and activity of AURKB were both reduced. It was
shown that methylation of Arg887 was essential for proper chro-
mosomal segregation and cell division in A549 or HeLa cells30. Our
structures show that Arg887 plays a key role binding to pS894 and
also forming part of the substrate binding groove (Fig. 1b, g).
Methylation of Arg887 would reduce the partial positive charge on
its side chain, and reduce the strength of its interaction of pS894.
This in turn would reduce the afﬁnity of INCENP for AURKB/
AURKC, as seen by Deng et al., although it may be the change in
substrate selectivity or KM that is more signiﬁcant in terms of
activation of AURKB or phosphorylation of H3S10.
McKenzie et al. showed that citron kinase (CIT) phosphorylates
the INCENP TSS motif, increasing AURKB activity, while AURKB
phosphorylated CIT on its coiled-coil domain, which localised CIT to
the mitotic spindle31. This additional example of synergistic activa-
tion and localisation via phosphorylation at the INCENP TSS motif
emphasises that there is still much to learn about the roles and
regulation of Aurora kinases in mitotic cell division.
PKCε phosphorylates AURKB at Ser227 which alters the
substrate selectivity of AURKB towards a particular set of sub-
strates, and this switch is essential for the completion of cell
division after the abscission checkpoint32. AURKB Ser227 is
equivalent to AURKC Ser193 (Fig. 1d) and this phosphorylation
site is on one of the activation loop serine residues that binds the
phosphorylated TSS motif (Fig. 1b). Phosphorylation at AURKB
Ser227 may compete with INCENP binding and change the
conformation of the activation loop and INCENP in this region,
thus changing the substrate selectivity. Interestingly, the only
activation loop residue not conserved between AURKB and
AURKC is AURKC Thr191 which is an alanine in AURKB.
Therefore the binding of INCENP pS893 is likely to be less strong
to AURKB than AURKC, and therefore AURKB Ser227 corre-
spondingly more available for phosphorylation by PKCε.
Petsalaki et al. reported that phosphorylation of AURKB at Ser331
by CHEK1 is required for full AURKB activation and that this
phosphorylation is present during mitosis33. Ser331 is in a highly
conserved region of AURKB and AURKC, but it is located on the
opposite site of AURKB/AURKC from the INCENP TSS motif, and
so it must be a different mechanism of activation from that of the
TSS motif analysed here. Petsalaki et al. also showed that Ser331
phosphorylation was required for TSS motif phosphorylation in cells.
In vitro, as we and others have shown, the INCENP TSS motif is
readily phosphorylated by AURKB/AURKC, so it may be that other
cellular components, possibly in the CPC, are exerting a regulatory
effect.
Interfering with INCENP TSS motif binding to AURKB or
AURKC may be an interesting anti-mitotic strategy. An inhibitor
acting in this way could potentially have pleiotropic effects of (i)
reducing AURKB or AURKC activity, or (ii) altering substrate
selectivity, or (iii) modifying the protein scaffolding in the CPC, and
(iv) achieving all of these while not completely abolishing kinase
activity. Given the complex role of the Aurora:INCENP interaction in
regulating the spatiotemporal events in mitosis/meiosis, the potential
cellular results of inhibition through such a mechanism are unclear.
Such an inhibitor would have a very different proﬁle from any
Aurora kinase inhibitor that has been previously tried in the clinic.
Finally, the conformational change induced by VX-680, and resultant
weakening of INCENP binding, is illustrative of the changes in
protein scaffolding that can be induced even by orthosteric kinase
inhibitors. It is an open question to what extent differing effects of
Aurora kinase inhibitors may be due to weakening of INCENP
binding and/or alteration of substrate binding.
Methods
Cloning. DNA for various residue ranges of human Aurora kinase C or human
Aurora kinase B were PCR ampliﬁed and subcloned into the ﬁrst cloning site of an
in-house pET-Duet based bi-cistronic vector pHTvAmp1-SGC (Supplementary
Table 1). DNA for residues 835–903 of human INCENP (NP_001035784.1) was
PCR ampliﬁed and subcloned into the second cloning site of the same plasmid. The
resulting constructs expressed the desired protein complex with an N-terminal
hexahistidine tag and TEV (tobacco etch virus) protease tag cleavage site for
Aurora kinase B/C (extension MGSSHHHHHHSQDPENLYFQ*GANS where
asterisk (*) represents the TEV protease digestion site), and an additional N-
terminal methionine for INCENP. The constructs were veriﬁed by DNA sequen-
cing. Primer sequences can be found in Supplementary Table 1.
The Aurora A expression plasmid which includes residues 122–403 of human
Aurora A (NP_003591.2) with a TEV protease cleavable hexahistidine tag, and the
TPX2 expression plasmid which includes residues 1–44 of human TPX2, were kind
gifts from Prof. Richard Bayliss.
Protein expression and puriﬁcation. After testing protein expression levels of the
constructs in small scale cultures, selected AURKB:INCENP and AURKC:INCENP
complexes were puriﬁed on a larger scale by the same method: The constructs were
transformed into BL21(DE3) cells (SGC) that contained the pRARE2 plasmid from
commercial Rosetta2 cells. The resulting colonies were used to inoculate 50mL of LB
media containing 100 µgmL−1 ampicillin and 34 µgmL-1 chloramphenicol which was
left shaking at 37 °C overnight. This culture was used to inoculate 1 L volumes of LB
media containing 80 µgmL-1 ampicillin at a ratio of 10mL culture to 1 L fresh media.
The cultures were grown at 37 °C with shaking until an OD600 of 0.5 was reached. The
temperature was reduced to 20 °C, and when the OD600 reached 0.7 isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to a ﬁnal concentration of 0.5mM and the
cultures were left overnight. Cells were harvested by centrifugation, re-suspended in
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Binding Buffer (50mM HEPES pH 7.5, 500mM NaCl, 20mM imidazole, 5% glycerol,
0.5mM tris(2-carboxyethyl)phosphine (TCEP)).
The re-suspended cells were lysed by sonication, polyethylenimine (PEI) was
added to a ﬁnal concentration of 0.15%, and the insoluble debris was removed by
centrifugation. The supernatant was passed through a column of 5 mL Ni-
Sepharose resin (GE Healthcare). The resin was washed with Binding Buffer
containing increasing amounts of imidazole before elution with Binding Buffer
containing 250 mM imidazole. TEV protease was added to the eluate, which was
dialysed into 20 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP
(GF Buffer) overnight at 4 °C. The protein complex was further puriﬁed by passing
through a gravity column of 5 mL Ni-Sepharose. The ﬂow-through was collected
and the column was washed with GF Buffer containing 30, 60, 90, 120 and 250 mM
imidazole. The fractions containing the pure protein complex were pooled,
concentrated to 5 mL and injected on a S75 16/60 gel ﬁltration column (GE
Healthcare) pre-equilibrated into GF Buffer. Fractions containing the Aurora:
INCENP complex were pooled and concentrated by ultraﬁltration. Protein
identities were conﬁrmed by electrospray ionisation mass spectrometry (ESI-MS).
AURKA was expressed and puriﬁed similarly to AURKB:INCENP, and TPX2
was puriﬁed on GST-Sepharose resin (GE Healthcare) in a buffer consisting of
50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM tris(2-carboxyethyl)
phosphine (TCEP), with elution performed using the same buffer with the addition
of 10 mM reduced glutathione.
Mutagenesis. Mutations were introduced by PCR into the INCENP coding DNA
sequence of the expression plasmids for the AURKB:INCENP or AURKC:INCENP
complexes. As the mutations were close together it was possible to create single or
multiple mutations within the same PCR primer. The mutated constructs were
veriﬁed by DNA sequencing. Mutant protein complexes were produced from the
modiﬁed plasmids using identical expression and puriﬁcation procedures as for the
wild-type protein. Protein identities were conﬁrmed by ESI-MS.
Crystallisation and data collection. Crystals were obtained using the sitting drop
vapour diffusion method at 4 °C.
Crystals of AURKC:INCENP:BRD-7880 grew from a mixture of 50 nL protein
(7.5 mgmL−1) and 100 nL of a well solution containing 0.2 M sodium chloride,
25% PEG3350 and 0.1 M HEPES pH 7.5. Crystals were equilibrated into reservoir
solution plus 25% ethylene glycol before cryo-cooling in liquid nitrogen.
Crystals of AURKC:INCENP:VX-680 grew from a mixture of 100 nL protein (8.7
mgmL−1) and 50 nL of a well solution containing 20% PEG3350, 10% ethylene glycol,
0.1M bis-tris-propane pH 7.5, 0.2M sodium sulfate. Crystals were equilibrated into
reservoir solution containing 25% ethylene glycol before freezing in liquid nitrogen.
Crystals of AURKA:BRD-7880 grew from a mixture of 100 nL protein
(27 mgmL−1) and 50 nL of a well solution containing 0.2 M potassium citrate,
0.1 M Bis-Tris propane pH 7.5, 20% PEG 3350, 10% ethylene glycol. Crystals were
equilibrated into reservoir solution containing 25% ethylene glycol before freezing
in liquid nitrogen.
All data was collected at 100 K at the Diamond Synchrotron. Data collection
statistics can be found in Table 1. Protein concentrations were measured by UV
absorbance, using the calculated molecular weights and estimated extinction
coefﬁcients using a NanoDrop spectrophotometer (Thermo Scientiﬁc).
Structure determination. The diffraction data was indexed and integrated using
MOSFLM34 or XDS35, and scaled using AIMLESS36. The AURKC:INCENP:BRD-
7880 structure was solved by molecular replacement using PHASER37 and the
structure of human AURKB as a search model (PDB ID 4AF315). There was one
molecule of the AURKC:INCENP complex in the asymmetric unit. The model was
built using Coot38 and reﬁned with REFMAC539. In the ﬁrst cycle of model
building 40 cycles of jelly-body reﬁnement in REFMAC5 reduced the Rfree from
0.52 to 0.45. After a subsequent cycle of deletion of atoms not matching the
electron density (Rfree= 0.44), where the INCENP coordinates matched those seen
in the AURKB:INCENP structure these coordinates were added to the model.
Rebuilding and reﬁnement resulted in the ﬁnal model.
The AURKC:INCENP:VX-680 structure was solved by molecular replacement using
PHASER and the structure with BRD-7880 as a search model. Rebuilding and
reﬁnement in REFMAC5 resulted in the ﬁnal model. The AURKA:BRD-7880 structure
was solved by molecular replacement using PHASER and a previous structure of
Aurora A (PDB ID 2J4Z40) as a search model. Rebuilding and reﬁnement in REFMAC5
resulted in the ﬁnal model. All models were validated using MOLPROBITY41.
Enzymatic assays. The protein samples for enzymatic assays were all puriﬁed on
the same day under identical conditions (Supplementary Fig. 12). Assays were run
in black low volume 384-well plates in a total volume of 25 µL. Each well contained
10 µL kinase reaction (2.5× concentration), 5 µL ADP detection reagent A (5×) and
10 µL ADP detection reagent B (2.5×). Reagents A and B contained enzymes and
co-factors that coupled ADP production to conversion of Amplex Red to Resor-
uﬁn42. The ﬁnal 1× assay buffer (in 25 µL) was 150 mM NaCl, 15 mM HEPES pH
7.5, 5 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA. Triplicate measurements of
500 nM kinase:INCENP complex and varying peptide concentration were set up.
ATP was injected to a ﬁnal concentration of 20 µM after 10 measurement cycles.
Measurements were made by ﬂuorescence (excitation 530–10 nm, emission
590–20 nm) using a PheraStar FS plate reader (BMG Labtech).
For analysis of autophosphorylation the Aurora:INCENP complexes were at
500 nM and ATP was injected to a ﬁnal concentration of 10 µM.
BioLayer interferometry. The binding kinetics of BRD-7880 to the Aurora kinases
was determined by the BLI method using an Octet RED384 system (FortéBio). All of
the experiments were performed at 25 °C under buffer conditions of 20mM HEPES
pH 7.5, 500mM NaCl, 0.5mM TCEP. Constructs for biotinylated AURKA and
biotinylated AURKB:INCENP were cloned, expressed and puriﬁed as previously.
Biotinylation was conﬁrmed by ESI-MS. The biotinylated proteins were immobilised
onto Super Streptavidin biosensors, which were subsequently used in association and
dissociation measurements each performed for a time window of 600 s. The inter-
ference patterns from the protein-coated biosensors with no compound and the
uncoated biosensors with compound at corresponding concentrations were measured
as two sets of controls. After double referencing corrections, the subtracted binding
interference data were applied to the calculations of binding constants using the
FortéBio analysis software provided with the instrument.
Isothermal titration calorimetry. Measurements were made at 25 °C on a VP-ITC
machine (GE Healthcare). All proteins were dialysed overnight into a buffer
consisting of 50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP.
For AURKA and AURKB:INCENP the syringe was loaded with 0.2 mM protein
and 28 × 10 μL injections were made into the cell, which was ﬁlled with 0.02 mM
BRD-7880. For AURKA:TPX2 the syringe was loaded with 0.17 mM protein and
28 × 10 μL injections were made into the cell, which was ﬁlled with 0.017 mM
BRD-7880. Data was analysed using MicroCal and Origin software.
Native ion mobility mass spectrometry. The native ion mobility-mass spectro-
metry (IM-MS) measurements were performed on a Synapt G2 HDMS (Waters) under
conditions which preserve native structure43,44. The samples were buffer exchanged into
250mM ammonium acetate using Micro Bio-spin P6 columns (Bio-Rad), and sprayed
at gentle instrument tuning conditions using nano-electrospray ionisation with home-
made glass capillaries; spray capillary voltage 1.2 kV, sampling cone 30V, trap CE 5.0 V,
transfer CE 0.0 V, trap bias 45 V, nanoﬂow gas pressure 0.1 bar, backing pressure 3
mbar, source temperature 30 °C, IMS wave velocity 300m/s, IMS wave height 35 V. The
data were acquired and processed with Masslynx v4.1 software, and ion mobility drift
times extracted using Driftscope v2.3 (both Waters). The collision cross sections (CCS)
of the proteins were calibrated using known CCS values determined under native
conditions as described previously45.
Dephosphorylation assay. Protein samples of AURKB:INCENP or AURKC:
INCENP were prepared at a ﬁnal concentration of 1 mgmL−1 by dilution with
20 mM Hepes pH 7.5, 300 mM NaCl, 0.5 mM TCEP. MnCl2 was added to a ﬁnal
concentration of 1 mM and bacteriophage lambda phosphatase was added to a ﬁnal
concentration of 41 µg mL−1. Aliquots were removed periodically and immediately
mixed with 0.1% formic acid before analysis by ESI-MS.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Coordinates and structure factors have been deposited in the PDB under accession codes
6GR8, 6GR9 and 6GRA. The source data underlying Figs. 2a–c, Table 2 and
Supplementary Fig. 8 are provided as a Source Data ﬁle. Other data are available from the
corresponding author upon reasonable request.
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